Reuters Events | Pharma

Thought leadership and innovation for the Pharmaceutical Industry

Bringing a new product to market is complex, and launching in a new market is even more so. Within the post pandemic environment, there is a lot we can do to virtually to ensure effective drug establishment and distribution, from out-licensing, partnerships, virtual ad boards to engaging with payers and customers. Hence, opportunities to execute an effective product launch is within your reach.

To secure a successful commercialization strategy, we must educate, motivate and communicate with all stakeholders from across the launch journey, to maximize launch impact. Whether you're launching into familiar or unfamiliar markets, engaging key decision makers must happen as early as possible, in order to navigate the regulatory and market access landscape. From pre to post product commercialization, we must build relationships, drive new collaborations and leverage launch synergies to streamline product reviews and ensure appropriate uptake.

In this session the panel we will explore the key decisions that pharmaceutical companies should be considering early in the product journey, to ensure a successful end-to-end launch campaign.  

Business-critical insights from Merck, CSL Behring, Takeda and Innomar Strategies include:

• Effectively navigate the complexity around regulatory and market access submissions to execute a product launch campaign on time
• Discuss various approaches for salesforces to adapt to different launch strategies, in a virtual environment, to create more agile and versatile commercial models
• Leverage RWE generation for use in health technology assessments to optimize access
• Upscale your Patient Support Strategies (PSP) and logistics models to support your molecule and its lifecycle, through an integrated digital and human PSP model
• Review a real-life Canadian case study illustrating how to unlock your product potential upon regulatory approval and commercialization